Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.

Abstract

BACKGROUND:

non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress. However, the pathophysiology of NAFLD in type 2 diabetes with hyperlipidaemia is not fully known, as well as the utility of the commonly prescribed anti-diabetic and lipid-lowering drugs in ameliorating liver injury markers.

METHODS:

hepatic complications of type 2 diabetes with hyperlipidaemia and the effects of atorvastatin and metformin, isolated and in association, in systemic and hepatic inflammatory and oxidative stress markers were tested using genetic type 2 diabetic Goto-Kakizaki rats fed with a high-fat diet.

RESULTS:

the high-fat diet aggravated the overall metabolic state and the hepatic markers of injury. All treatments decreased fasting glycaemia, insulin resistance and free fatty acid levels. Combined treatment further decreased C-reactive protein (CRP), adiponectin, liver tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), systemic and hepatic oxidative stress and portal inflammation.

CONCLUSIONS:

our data provides evidence of a greater benefit with a combination of atorvastatin and metformin in improving liver injury in type 2 diabetes with hyperlipidaemia.

• Authors: P Matafome, T Louro, L Rodrigues, J Crisóstomo, E Nunes, C Amaral, P Monteiro, A Cipriano, R Seiça
• Journal: Diabetes/metabolism research and reviews (Diabetes Metab Res Rev) Vol. 27 Issue 1 Pg. 54-62 (Jan 2011) ISSN: 1520-7560 [Electronic] England
• PMID: 21218508 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: 2010 John Wiley & Sons, Ltd.

Chemical References

• Anticholesteremic Agents
• Drug Combinations
• Heptanoic Acids
• Hypoglycemic Agents
• Interleukin-6
• Pyrroles
• Tumor Necrosis Factor-alpha
• C-Reactive Protein
• Metformin
• Atorvastatin

Topics

• Animals
• Anticholesteremic Agents (pharmacology)
• Atorvastatin
• Body Weight (drug effects)
• C-Reactive Protein (metabolism)
• Diabetes Complications (drug therapy)
• Diabetes Mellitus, Experimental (drug therapy)
• Diabetes Mellitus, Type 2 (drug therapy)
• Drug Combinations
• Fatty Liver (prevention & control)
• Heptanoic Acids (pharmacology)
• Hyperlipidemias (complications, drug therapy)
• Hypoglycemic Agents (pharmacology)
• Insulin Resistance
• Interleukin-6 (metabolism)
• Liver (cytology, drug effects, metabolism)
• Metformin (pharmacology)
• Non-alcoholic Fatty Liver Disease
• Oxidative Stress (drug effects)
• Pyrroles (pharmacology)
• Rats
• Rats, Inbred Strains
• Tumor Necrosis Factor-alpha (metabolism)